An unconventional cancer treatment lacking clinical efficacy remains available to Italian cancer patients

Domenico Franco Merlo, Monica Beccaro, Massimo Costantini

Research output: Contribution to journalArticle

Abstract

Aims and background. An unconventional cancer treatment known as "Di Bella multitherapy" gained popularity among Italian cancer patients during the 90's. In 1999, it was shown to lack any detectable antitumor activity. Access to the multitherapy was investigated three years later within the post-bereavement Italian Survey of the Dying of Cancer (ISDOC), whose broader aim was to investigate the end-of-life care experiences of terminal cancer patients. Methods. ISDOC was carried out in a two-stage probability sample of 2,000 out of 160,000 Italian cancer patients deceased between March 2002 and June 2003. For each cancer patient, a non-professional caregiver, i.e., the closest and the best-informed person about her/his last three months of life, was identified. A specific question concerning the "Di Bella multitherapy" was included in a semi-structured questionnaire that was administered face-to-face to the caregivers by trained interviewers. Weighted estimates of the frequency of patients receiving the multitherapy in the target population and their 95% confidence intervals were computed by taking into account stratification and clustering of observations. Results. During their last three months of life, 0.7% (95% CI, 0.3-1.6) of terminal cancer patients, corresponding to some 1,100 subjects (range, 480-2,560), received the multitherapy. No statistically significant difference was observed for age at death, cancer type, gender, education, marital status, or residence. Conclusions. The finding indicates that an unconventional cancer treatment proven to lack clinical efficacy remained accessible to Italian cancer patients. Ethical, deontologic, and economic implications call for a routine monitoring of provision of and access to unproven cancer treatments.

Original languageEnglish
Pages (from-to)830-837
Number of pages8
JournalTumori
Volume94
Issue number6
Publication statusPublished - Nov 2008

Fingerprint

Neoplasms
Therapeutics
Caregivers
Bereavement
Sampling Studies
Terminal Care
Health Services Needs and Demand
Marital Status
Cluster Analysis
Economics
Confidence Intervals
Interviews
Education
Surveys and Questionnaires

Keywords

  • Ethics
  • Fraud
  • Survey
  • Terminal cancer patients
  • Unconventional cancer treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An unconventional cancer treatment lacking clinical efficacy remains available to Italian cancer patients. / Merlo, Domenico Franco; Beccaro, Monica; Costantini, Massimo.

In: Tumori, Vol. 94, No. 6, 11.2008, p. 830-837.

Research output: Contribution to journalArticle

@article{03fbce365c0f403487e5f63b1cc25018,
title = "An unconventional cancer treatment lacking clinical efficacy remains available to Italian cancer patients",
abstract = "Aims and background. An unconventional cancer treatment known as {"}Di Bella multitherapy{"} gained popularity among Italian cancer patients during the 90's. In 1999, it was shown to lack any detectable antitumor activity. Access to the multitherapy was investigated three years later within the post-bereavement Italian Survey of the Dying of Cancer (ISDOC), whose broader aim was to investigate the end-of-life care experiences of terminal cancer patients. Methods. ISDOC was carried out in a two-stage probability sample of 2,000 out of 160,000 Italian cancer patients deceased between March 2002 and June 2003. For each cancer patient, a non-professional caregiver, i.e., the closest and the best-informed person about her/his last three months of life, was identified. A specific question concerning the {"}Di Bella multitherapy{"} was included in a semi-structured questionnaire that was administered face-to-face to the caregivers by trained interviewers. Weighted estimates of the frequency of patients receiving the multitherapy in the target population and their 95{\%} confidence intervals were computed by taking into account stratification and clustering of observations. Results. During their last three months of life, 0.7{\%} (95{\%} CI, 0.3-1.6) of terminal cancer patients, corresponding to some 1,100 subjects (range, 480-2,560), received the multitherapy. No statistically significant difference was observed for age at death, cancer type, gender, education, marital status, or residence. Conclusions. The finding indicates that an unconventional cancer treatment proven to lack clinical efficacy remained accessible to Italian cancer patients. Ethical, deontologic, and economic implications call for a routine monitoring of provision of and access to unproven cancer treatments.",
keywords = "Ethics, Fraud, Survey, Terminal cancer patients, Unconventional cancer treatment",
author = "Merlo, {Domenico Franco} and Monica Beccaro and Massimo Costantini",
year = "2008",
month = "11",
language = "English",
volume = "94",
pages = "830--837",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - An unconventional cancer treatment lacking clinical efficacy remains available to Italian cancer patients

AU - Merlo, Domenico Franco

AU - Beccaro, Monica

AU - Costantini, Massimo

PY - 2008/11

Y1 - 2008/11

N2 - Aims and background. An unconventional cancer treatment known as "Di Bella multitherapy" gained popularity among Italian cancer patients during the 90's. In 1999, it was shown to lack any detectable antitumor activity. Access to the multitherapy was investigated three years later within the post-bereavement Italian Survey of the Dying of Cancer (ISDOC), whose broader aim was to investigate the end-of-life care experiences of terminal cancer patients. Methods. ISDOC was carried out in a two-stage probability sample of 2,000 out of 160,000 Italian cancer patients deceased between March 2002 and June 2003. For each cancer patient, a non-professional caregiver, i.e., the closest and the best-informed person about her/his last three months of life, was identified. A specific question concerning the "Di Bella multitherapy" was included in a semi-structured questionnaire that was administered face-to-face to the caregivers by trained interviewers. Weighted estimates of the frequency of patients receiving the multitherapy in the target population and their 95% confidence intervals were computed by taking into account stratification and clustering of observations. Results. During their last three months of life, 0.7% (95% CI, 0.3-1.6) of terminal cancer patients, corresponding to some 1,100 subjects (range, 480-2,560), received the multitherapy. No statistically significant difference was observed for age at death, cancer type, gender, education, marital status, or residence. Conclusions. The finding indicates that an unconventional cancer treatment proven to lack clinical efficacy remained accessible to Italian cancer patients. Ethical, deontologic, and economic implications call for a routine monitoring of provision of and access to unproven cancer treatments.

AB - Aims and background. An unconventional cancer treatment known as "Di Bella multitherapy" gained popularity among Italian cancer patients during the 90's. In 1999, it was shown to lack any detectable antitumor activity. Access to the multitherapy was investigated three years later within the post-bereavement Italian Survey of the Dying of Cancer (ISDOC), whose broader aim was to investigate the end-of-life care experiences of terminal cancer patients. Methods. ISDOC was carried out in a two-stage probability sample of 2,000 out of 160,000 Italian cancer patients deceased between March 2002 and June 2003. For each cancer patient, a non-professional caregiver, i.e., the closest and the best-informed person about her/his last three months of life, was identified. A specific question concerning the "Di Bella multitherapy" was included in a semi-structured questionnaire that was administered face-to-face to the caregivers by trained interviewers. Weighted estimates of the frequency of patients receiving the multitherapy in the target population and their 95% confidence intervals were computed by taking into account stratification and clustering of observations. Results. During their last three months of life, 0.7% (95% CI, 0.3-1.6) of terminal cancer patients, corresponding to some 1,100 subjects (range, 480-2,560), received the multitherapy. No statistically significant difference was observed for age at death, cancer type, gender, education, marital status, or residence. Conclusions. The finding indicates that an unconventional cancer treatment proven to lack clinical efficacy remained accessible to Italian cancer patients. Ethical, deontologic, and economic implications call for a routine monitoring of provision of and access to unproven cancer treatments.

KW - Ethics

KW - Fraud

KW - Survey

KW - Terminal cancer patients

KW - Unconventional cancer treatment

UR - http://www.scopus.com/inward/record.url?scp=61349100762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349100762&partnerID=8YFLogxK

M3 - Article

C2 - 19267100

AN - SCOPUS:61349100762

VL - 94

SP - 830

EP - 837

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -